# Jean A Boutin

List of Publications by Year
in descending order



| 262 | 10,064 | 34105 52 | 51608 86 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 268 | 268 | 268 | 9717 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Identification of the Melatonin-binding SiteMT 3 as the Quinone Reductase 2. Journal of Biological Chemistry, 2000, 275, 31311-31317. | 3.4 | 493 |
| 2 | Myristoylation. Cellular Signalling, 1997, 9, 15-35. | 3.6 | 362 |
| 3 | Peroxisome Proliferator-activated Receptor Î³ (PPARÎ³) as a Molecular Target for the Soy Phytoestrogen Genistein. Journal of Biological Chemistry, 2003, 278, 962-967. | 3.4 | 289 |
| 4 | Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?. British Journal of Pharmacology, 2008, 154, 1182-1195. | 5.4 | 244 |
| 5 | New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 367, 553-561. | 3.0 | 224 |
| 6 | Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation. Journal of Biological Chemistry, 2003, 278, 18162-18169. | 3.4 | 207 |
| 7 | Molecular tools to study melatonin pathways and actions. Trends in Pharmacological Sciences, 2005, 26, 412-419. | 8.7 | 205 |
| 8 | Comparative pharmacological studies of melatonin receptors: mt1, mt2 and mt3/qr2. tissue distribution of mt3/qr2 11Abbreviations: MCA-NAT, methoxy-carbonylamino-N-acetyltrypta- mine, 2-[125I]-I-MCA-NAT, 2-[125I]-iodomethoxy-carbonylamino-N-acetyltryptamine; 2-IbMT, 2-iodo-N-butanoyl-5-methoxytryptamine; 4-P-PDOT, 4-phenyl-2-propionamido-tetraline; DH97, N-pentanoyl-2-benzyltryptamine; S20760, 5-methoxy-N-cyclopropanoyl-tryptamine; S24635, | | |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia, 2005, 48, 569-577. | 6.3 | 104 |
| 20 | Cloning and Characterization of the 5â€² Flanking Region of the Human Uncoupling Protein 3 (UCP3) Gene. Biochemical and Biophysical Research Communications, 1999, 258, 278-283. | 2.1 | 101 |
| 21 | Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. British Journal of Pharmacology, 2007, 150, 37-46. | 5.4 | 89 |
| 22 | S32826, A Nanomolar Inhibitor of Autotaxin: Discovery, Synthesis and Applications as a Pharmacological Tool. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 809-819. | 2.5 | 89 |
| 23 | Synthesis and Structureâ^'Affinityâ^'Activity Relationships of Novel Benzofuran Derivatives as MT2 Melatonin Receptor Selective Ligands. Journal of Medicinal Chemistry, 2002, 45, 2788-2800. | 6.4 | 88 |
| 24 | Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. Molecular Pharmacology, 2001, 60, 632-9. | 2.3 | 86 |
| 25 | Detergent-free Isolation of Functional G Protein-Coupled Receptors into Nanometric Lipid Particles. Biochemistry, 2016, 55, 38-48. | 2.5 | 85 |
| 26 | New ligands at theÂmelatonin binding site MT3. European Journal of Medicinal Chemistry, 2006, 41, 306-320. | 5.5 | 83 |
| 27 | Genomic organization and characterization of splice variants of the human histamine H3 receptor. Biochemical Journal, 2001, 355, 279. | 3.7 | 83 |
| 28 | Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochemical Journal, 2008, 413, 81-91. | 3.7 | 81 |
| 29 | Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Proteinâ€“Ligand Residence Times. Journal of Medicinal Chemistry, 2016, 59, 7167-7176. | 6.4 | 81 |
| 30 | Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA). Journal of Neuroscience, 2011, 31, 16928-16940. | 3.6 | 80 |
| 31 | S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab. Molecular Cancer Therapeutics, 2013, 12, 1749-1762. | 4.1 | 78 |
| 32 | Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochemical Journal, 2005, 388, 205-215. | 3.7 | 73 |
| 33 | Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding siteMT3. FEBS Letters, 2004, 578, 116-120. | 2.8 | 72 |
| 34 | Quinone reductase 2 as a promising target of melatonin therapeutic actions. Expert Opinion on Therapeutic Targets, 2016, 20, 303-317. | 3.4 | 71 |
| 35 | High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H44-H53. | 3.2 | 70 |
| 36 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase activities. Biochemical Pharmacology, 1985, 34, 2235-2249. | 4.4 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Post-translational Modification of Bid Has Differential Effects on Its Susceptibility to Cleavage by Caspase 8 or Caspase 3. Journal of Biological Chemistry, 2003, 278, 15749-15757. | 3.4 | 67 |
| 38 | Combinatorial Peptide Libraries: Robotic Synthesis and Analysis by Nuclear Magnetic Resonance, Mass Spectrometry, Tandem Mass Spectrometry, and High-Performance Capillary Electrophoresis Techniques. Analytical Biochemistry, 1996, 234, 126-141. | 2.4 | 65 |
| 39 | Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 2517-2528. | 3.0 | 63 |
| 40 | Design and Synthesis of Naphthalenic Dimers as Selective MT1Melatoninergic Ligands. Journal of Medicinal Chemistry, 2003, 46, 1127-1129. | 6.4 | 61 |
| 41 | Structure-Activity Relationship Studies of Melanin-concentrating Hormone (MCH)-related Peptide Ligands at SLC-1, the Human MCH Receptor. Journal of Biological Chemistry, 2001, 276, 13554-13562. | 3.4 | 59 |
| 42 | Substrate Specificity and Inhibition Studies of Human SerotoninN-Acetyltransferase. Journal of Biological Chemistry, 2000, 275, 8794-8805. | 3.4 | 58 |
| 43 | Tyrosine protein kinase inhibition and cancer. International Journal of Biochemistry & Cell Biology, 1994, 26, 1203-1226. | 0.5 | 57 |
| 44 | Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. FEBS Letters, 2007, 581, 3572-3578. | 2.8 | 57 |
| 45 | Melatonin from Cerebrospinal Fluid but Not from Blood Reaches Sheep Cerebral Tissues Under Physiological Conditions. Journal of Neuroendocrinology, 2014, 26, 151-163. | 2.6 | 57 |
| 46 | Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 174-183. | 0.8 | 56 |
| 47 | GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4501-4506. | 7.1 | 55 |
| 48 | Is There Sufficient Evidence that the Melatonin Binding SiteMT<sub>3</sub>Is Quinone Reductase 2?. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 59-65. | 2.5 | 55 |
| 49 | Food intake regulation in rodents: Y5 or Y1 NPY receptors or both?. Canadian Journal of Physiology and Pharmacology, 2000, 78, 173-185. | 1.4 | 54 |
| 50 | Therapeutic Perspectives for Melatonin Agonists and Antagonists. Journal of Neuroendocrinology, 2003, 15, 442-448. | 2.6 | 54 |
| 51 | The end of a myth: cloning and characterization of the ovine melatonin MT<sub>2</sub> receptor. British Journal of Pharmacology, 2009, 158, 1248-1262. | 5.4 | 54 |
| 52 | Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence. Journal of Pineal Research, 2010, 48, 263-269. | 7.4 | 54 |
| 53 | Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs. Journal of Pharmacology and Experimental Therapeutics, 1999, 290, 334-40. | 2.5 | 54 |
| 54 | Insights into the redox cycle of human quinone reductase 2. Free Radical Research, 2011, 45, 1184-1195. | 3.3 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions. Frontiers in Neuroendocrinology, 2011, 32, 387-397. | 5.2 | 53 |
| 56 | The active conformation of human glucokinase is not altered by allosteric activators. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 929-935. | 2.5 | 53 |
| 57 | Melatonin <scp>MT<sub>1</sub></scp> and <scp>MT<sub>2</sub></scp> receptors display different molecular pharmacologies only in the <scp>G</scp>â€protein coupled state. British Journal of Pharmacology, 2014, 171, 186-201. | 5.4 | 51 |
| 58 | Binding of prostaglandins to human PPARÎ³: tool assessment and new natural ligands. European Journal of Pharmacology, 2001, 417, 77-89. | 3.5 | 50 |
| 59 | Melanin-concentrating hormone and its receptors: state of the art. Canadian Journal of Physiology and Pharmacology, 2002, 80, 388-395. | 1.4 | 50 |
| 60 | Expression and regulation of the nuclear receptor RORÎ± in human vascular cells. FEBS Letters, 2002, 511, 36-40. | 2.8 | 50 |
| 61 | Loss of Quinone Reductase 2 Function Selectively Facilitates Learning Behaviors. Journal of Neuroscience, 2010, 30, 12690-12700. | 3.6 | 49 |
| 62 | Quinone reductase 2 substrate specificity and inhibition pharmacology. Chemico-Biological Interactions, 2005, 151, 213-228. | 4.0 | 48 |
| 63 | Expression of UCP3 in CHO cells does not cause uncoupling, but controls mitochondrial activity in the presence of glucose. Biochemical Journal, 2006, 393, 431-439. | 3.7 | 48 |
| 64 | Resistance to high-fat-diet-induced obesity and sexual dimorphism in the metabolic responses of transgenic mice with moderate uncoupling protein 3 overexpression in glycolytic skeletal muscles. Diabetologia, 2007, 50, 2190-2199. | 6.3 | 48 |
| 65 | The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells. Scientific Reports, 2019, 9, 11829. | 3.3 | 48 |
| 66 | Binding Kinetics of Glucose and Allosteric Activators to Human Glucokinase Reveal Multiple Conformational States. Biochemistry, 2009, 48, 5466-5482. | 2.5 | 47 |
| 67 | Old and new inhibitors of quinone reductase 2. Chemico-Biological Interactions, 2010, 186, 103-109. | 4.0 | 47 |
| 68 | Highly Potent and Selective MT<sub>2</sub> Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines. Journal of Medicinal Chemistry, 2015, 58, 7512-7525. | 6.4 | 47 |
| 69 | Myristoyl-CoA: protein N-myristoyltransferase activity in cancer cells. Purification and characterization of a cytosolic isoform from the murine leukemia cell line L1210. FEBS Journal, 1993, 214, 853-867. | 0.2 | 46 |
| 70 | Therapeutic Potential of Melatonin Ligands. Chronobiology International, 2006, 23, 413-418. | 2.0 | 45 |
| 71 | Autotaxin. Cellular and Molecular Life Sciences, 2009, 66, 3009-3021. | 5.4 | 44 |
| 72 | A Dimeric Sesquiterpenoid from a Malaysian Meiogyne as a New Inhibitor of Bcl-xL/BakBH3 Domain Peptide Interaction. Journal of Natural Products, 2009, 72, 480-483. | 3.0 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Food intake regulation in rodents: Y<sub>5</sub> or Y<sub>1</sub> NPY receptors or both?. Canadian Journal of Physiology and Pharmacology, 2000, 78, 173-185. | 1.4 | 42 |
| 74 | [125 I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor. British Journal of Pharmacology, 2001, 133, 371-378. | 5.4 | 41 |
| 75 | Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochemical Pharmacology, 2008, 75, 2007-2019. | 4.4 | 41 |
| 76 | Assessment of the Mulder and Van Doorn kinetic procedure and rapid centrifugal analysis of UDP-glucuronosyltransferase activities. Journal of Proteomics, 1984, 9, 69-79. | 2.4 | 40 |
| 77 | Synthesis of Nitroindole Derivatives with High Affinity and Selectivity for Melatoninergic Binding SitesMT3. Journal of Medicinal Chemistry, 2002, 45, 1853-1859. | 6.4 | 39 |
| 78 | Covalent binding of 15-deoxy-delta12,14-prostaglandin J2 to PPARÎ³. Biochemical and Biophysical Research Communications, 2005, 337, 521-525. | 2.1 | 39 |
| 79 | Oxidative stress and neurodegeneration: The possible contribution of quinone reductase 2. Free Radical Biology and Medicine, 2018, 120, 56-61. | 2.9 | 39 |
| 80 | Melatonin receptor ligands: A pharmacoâ€chemical perspective. Journal of Pineal Research, 2020, 69, e12672. | 7.4 | 39 |
| 81 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferase(s) activities: Comparison between human and mammalian species activities. Chemico-Biological Interactions, 1984, 52, 173-184. | 4.0 | 38 |
| 82 | Xâ€ray structural studies of quinone reductase 2 nanomolar range inhibitors. Protein Science, 2011, 20, 1182-1195. | 7.6 | 38 |
| 83 | In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones. Free Radical Biology and Medicine, 2015, 89, 126-134. | 2.9 | 38 |
| 84 | Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells. PLoS ONE, 2011, 6, e17237. | 2.5 | 38 |
| 85 | Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochemical Pharmacology, 2004, 67, 667-677. | 4.4 | 37 |
| 86 | MT3/QR2 melatonin binding site does not use melatonin as a substrate or a coâ€substrate. Journal of Pineal Research, 2008, 45, 524-531. | 7.4 | 37 |
| 87 | Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 753-759. | 3.0 | 36 |
| 88 | 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part I: Synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1617-1622. | 2.2 | 36 |
| 89 | Use of hydrophilic interaction chromatography for the study of tyrosine protein kinase specificity. Biomedical Applications, 1992, 583, 137-143. | 1.7 | 35 |
| 90 | Synthesis of Phenalene and Acenaphthene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors. Journal of Medicinal Chemistry, 2000, 43, 4051-4062. | 6.4 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Regulation of murine airway responsiveness by endothelial nitric oxide synthase. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L258-L267. | 2.9 | 35 |
| 92 | Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus). PLoS ONE, 2018, 13, e0191904. | 2.5 | 35 |
| 93 | Melatonin controversies, an update. Journal of Pineal Research, 2021, 70, e12702. | 7.4 | 35 |
| 94 | Molecular and cellular pharmacological properties of 5â€•methoxycarbonylaminoâ€•N â€•acetyltryptamine (MCAâ€NAT): a nonspecific MT3 ligand. Journal of Pineal Research, 2010, 48, 222-229. | 7.4 | 34 |
| 95 | Structureâ€“Activity Relationships of a Series of Analogues of the RFamide-Related Peptide 26RFa. Journal of Medicinal Chemistry, 2011, 54, 4806-4814. | 6.4 | 34 |
| 96 | Cytotoxic Pentacyclic Triterpenoids from Combretum sundaicum and Lantana camara as Inhibitors of Bcl-xL/BakBH3 Domain Peptide Interaction. Journal of Natural Products, 2009, 72, 1314-1320. | 3.0 | 33 |
| 97 | Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. Chemico-Biological Interactions, 2016, 258, 115-125. | 4.0 | 32 |
| 98 | NPY receptor subtypes involved in the contraction of the proximal colon of the rat. Regulatory Peptides, 1998, 75-76, 221-229. | 1.9 | 31 |
| 99 | NPY receptor subtype in the rabbit isolated ileum. British Journal of Pharmacology, 1999, 127, 795-801. | 5.4 | 31 |
| 100 | A Generic Approach for the Purification of Signaling Complexes That Specifically Interact with the Carboxyl-terminal Domain of G Protein-coupled Receptors. Molecular and Cellular Proteomics, 2008, 7, 1556-1569. | 3.8 | 31 |
| 101 | Microfluidic platform for optimization of crystallization conditions. Journal of Crystal Growth, 2017, 472, 18-28. | 1.5 | 31 |
| 102 | Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERBÎ±/NCoR. Journal of Computer-Aided Molecular Design, 2017, 31, 755-775. | 2.9 | 31 |
| 103 | SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study. Journal of Pharmacology and Experimental Therapeutics, 2001, 299, 137-46. | 2.5 | 31 |
| 104 | Selection of a histidine-containing inhibitor of gelatinases through deconvolution of combinatorial tetrapeptide libraries. Molecular Diversity, 1997, 2, 135-146. | 3.9 | 30 |
| 105 | Combinatorial chemistry for the generation of molecular diversity and the discovery of bioactive leads. Chemometrics and Intelligent Laboratory Systems, 1998, 43, 43-68. | 3.5 | 30 |
| 106 | Meganuclease-Driven Targeted Integration in CHO-K1 Cells for the Fast Generation of HTS-Compatible Cell-Based Assays. Journal of Biomolecular Screening, 2010, 15, 956-967. | 2.6 | 30 |
| 107 | Gene expression profiling during hibernation in the European hamster. Scientific Reports, 2018, 8, 13167. | 3.3 | 30 |
| 108 | Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European Journal of Medicinal Chemistry, 2012, 49, 310-323. | 5.5 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors. International Journal of Molecular Sciences, 2013, 14, 8948-8962. | 4.1 | 29 |
| 110 | Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors. European Journal of Medicinal Chemistry, 2004, 39, 515-526. | 5.5 | 28 |
| 111 | Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human Î±1A-adrenoceptors. Biochemical Journal, 1999, 343, 231. | 3.7 | 27 |
| 112 | The Emergence of Selective 5-HT2B Antagonists Structures, Activities and Potential Therapeutic Applications [General Reviews]. Mini-Reviews in Medicinal Chemistry, 2004, 4, 325-330. | 2.4 | 27 |
| 113 | Rational Design of a Low Molecular Weight, Stable, Potent, and Long-Lasting GPR103 Aza-Î²3-pseudopeptide Agonist. Journal of Medicinal Chemistry, 2012, 55, 7516-7524. | 6.4 | 27 |
| 114 | Ligand modulation of [35S]GTPÎ³S binding at human Î±2A, Î±2B and Î±2C adrenoceptors. Cellular Signalling, 2002, 14, 829-837. | 3.6 | 25 |
| 115 | Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. European Journal of Medicinal Chemistry, 2011, 46, 1835-1840. | 5.5 | 24 |
| 116 | Molecular pharmacology of the mouse melatonin receptors MT1 and MT2. European Journal of Pharmacology, 2012, 677, 15-21. | 3.5 | 24 |
| 117 | Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 681-692. | 2.5 | 24 |
| 118 | Combinatorial peptide synthesis: statistical evaluation of peptide distribution. Trends in Pharmacological Sciences, 1996, 17, 8-12. | 8.7 | 23 |
| 119 | Appetite-Boosting Property of Pro-Melanin-Concentrating Hormone131â€“165 (Neuropeptide-Glutamic) Tj ETQq1 1 0.784314 rgBT /Ov Therapeutics, 2002, 302, 766-773. | 2.5 | 22 |
| 120 | A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor. International Journal of Obesity, 2004, 28, 628-639. | 3.4 | 22 |
| 121 | A Simple Theoretical Model for Fluorescence Polarization Binding Assay Development. Journal of Biomolecular Screening, 2006, 11, 949-958. | 2.6 | 22 |
| 122 | Synthesis of 3-phenylnaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2008, 16, 8339-8348. | 3.0 | 22 |
| 123 | Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT<sub>1</sub> and MT<sub>2</sub> receptors. Pharmacology Research and Perspectives, 2020, 8, e00539. | 2.4 | 22 |
| 124 | Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme. Molecular Pharmacology, 2020, 98, 620-633. | 2.3 | 22 |
| 125 | Integrated system for the screening of the specificity of protein kinase inhibitors. Biochemical Pharmacology, 1993, 46, 439-448. | 4.4 | 21 |
| 126 | Investigation of S-Farnesyl Transferase Substrate Specificity with Combinatorial Tetrapeptide Libraries. Cellular Signalling, 1999, 11, 59-69. | 3.6 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform. Biochemical Journal, 2003, 369, 667-673. | 3.7 | 21 |
| 128 | Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes. Journal of Pineal Research, 2007, 43, 10-15. | 7.4 | 21 |
| 129 | Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2010, 18, 3426-3436. | 3.0 | 21 |
| 130 | Recombinant Human Melatonin Receptor MT1 Isolated in Mixed Detergents Shows Pharmacology Similar to That in Mammalian Cell Membranes. PLoS ONE, 2014, 9, e100616. | 2.5 | 21 |
| 131 | S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization. Molecular Pharmacology, 2019, 95, 269-285. | 2.3 | 21 |
| 132 | S18986: A positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures. European Journal of Pharmacology, 2007, 561, 23-31. | 3.5 | 20 |
| 133 | Indirect Evidences of Udp-Glucuronosyltransferase Heterogeneity: How Can it Help Purification?. Drug Metabolism Reviews, 1987, 18, 517-551. | 3.6 | 19 |
| 134 | Evaluation of high performance liquid chromatography/electrospray mass spectrometry with selected ion monitoring for the analysis of large synthetic combinatorial peptide libraries. Rapid Communications in Mass Spectrometry, 1997, 11, 1971-1976. | 1.5 | 19 |
| 135 | Comparative analysis of melanin-concentrating hormone structure and activity in fishes and mammals. Peptides, 2004, 25, 1623-1632. | 2.4 | 19 |
| 136 | Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. Bioorganic and Medicinal Chemistry, 2009, 17, 2963-2974. | 3.0 | 19 |
| 137 | Camphoroquinone reduction: another reaction catalyzed by rat liver cytosol 3Î±-hydroxysteroid dehydrogenase. BBA - Proteins and Proteomics, 1986, 870, 463-472. | 2.1 | 18 |
| 138 | Limitations of the coupling of amino acid mixtures for the preparation of equimolar peptide libraries. Molecular Diversity, 1997, 3, 43-60. | 3.9 | 18 |
| 139 | Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis. Archives of Biochemistry and Biophysics, 2008, 477, 12-19. | 3.0 | 18 |
| 140 | Screening of protein kinase inhibitors identifies PKC inhibitors as inhibitors of osteoclastic acid secretion and bone resorption. BMC Musculoskeletal Disorders, 2010, 11, 250. | 1.9 | 18 |
| 141 | Description of the constitutive activity of cloned human melatonin receptors hMT<sub>1</sub> and hMT<sub>2</sub> and discovery of inverse agonists. Journal of Pineal Research, 2012, 53, 29-37. | 7.4 | 18 |
| 142 | New melatonin (MT1/MT2) ligands: Design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 986-996. | 3.0 | 18 |
| 143 | A Chemical Library to Screen Protein and Proteinâ€“Ligand Crystallization Using a Versatile Microfluidic Platform. Crystal Growth and Design, 2018, 18, 5130-5137. | 3.0 | 18 |
| 144 | Studies of UDP-glucuronosyltransferase activity toward eugenol, using a gas chromatographic method of measurement. Analytical Biochemistry, 1983, 135, 201-207. | 2.4 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. European Journal of Cancer & Clinical Oncology, 1989, 25, 1311-1316. | 0.7 | 17 |
| 146 | Assay of tyrosine protein kinase activity from HL-60 by high-performance liquid chromatography for specificity studies. Analytical Biochemistry, 1990, 190, 32-38. | 2.4 | 17 |
| 147 | Molecular pharmacology of adipocyte-secreted autotaxin. Chemico-Biological Interactions, 2008, 172, 115-124. | 4.0 | 17 |
| 148 | 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARÎ±/Î³ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2683-2687. | 2.2 | 17 |
| 149 | The five dimensions of receptor pharmacology exemplified by melatonin receptors: An opinion. Pharmacology Research and Perspectives, 2020, 8, e00556. | 2.4 | 17 |
| 150 | Inhibition studies of microsomal UDP-glucuronosyltransferase activities by furosemide and salicylamide. Pharmacological Research Communications, 1984, 16, 227-241. | 0.2 | 16 |
| 151 | Characterization and regulation of a CHO cell line stably expressing human serotonin N-acetyltransferase (EC 2.3.1.87). Cellular and Molecular Life Sciences, 2002, 59, 1395-1405. | 5.4 | 16 |
| 152 | Cellular knock-down of quinone reductase 2: A laborious road to successful inhibition by RNA interference. Biochimie, 2007, 89, 1264-1275. | 2.6 | 16 |
| 153 | Synthesis and Pharmacological Evaluation of a series of the Agomelatine Analogues as Melatonin MT<sub>1</sub>/MT<sub>2</sub> Agonist and 5â€HT<sub>2C</sub> Antagonist. ChemMedChem, 2013, 8, 1830-1845. | 3.2 | 16 |
| 154 | Assessments of cellular melatonin receptor signaling pathways: Î²-arrestin recruitment, receptor internalization, and impedance variations. European Journal of Pharmacology, 2018, 818, 534-544. | 3.5 | 16 |
| 155 | VHH characterization. Comparison of recombinant with chemically synthesized antiâ€HER2 VHH. Protein Science, 2019, 28, 1865-1879. | 7.6 | 16 |
| 156 | Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt 1 and MT 2 receptors. Bioorganic and Medicinal Chemistry, 2000, 8, 163-171. | 3.0 | 15 |
| 157 | New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors. FEBS Journal, 2004, 271, 418-428. | 0.2 | 15 |
| 158 | Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species. Protein Expression and Purification, 2004, 38, 84-98. | 1.3 | 15 |
| 159 | High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1. Acta Pharmacologica Sinica, 2008, 29, 752-758. | 6.1 | 15 |
| 160 | Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2316-2319. | 2.2 | 15 |
| 161 | Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 574-578. | 0.8 | 15 |
| 162 | Feature-Based Molecular Network-Guided Dereplication of Natural Bioactive Products from Leaves of Stryphnodendron pulcherrimum (Willd.) Hochr. Metabolites, 2021, 11, 281. | 2.9 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Drug-induced hydrogen peroxide production in isolated rat hepatocytes. Toxicology, 1989, 54, 129-137. | 4.2 | 14 |
| 164 | Studies of the potency of protein kinase inhibitors on ATPase activities. Chemico-Biological Interactions, 1993, 86, 17-27. | 4.0 | 14 |
| 165 | Uncoupling Protein-3 (UCP3) mRNA Expression in Reconstituted Human Muscle after Myoblast Transplantation in RAG2â^'/â^'/Î³c/C5â^' Immunodeficient Mice. Journal of Biological Chemistry, 2002, 277, 47407-47411. | 3.4 | 14 |
| 166 | Endothelin-1 inhibits TNFÎ± -induced iNOS expression in 3T3-F442A adipocytes. British Journal of Pharmacology, 2003, 139, 935-944. | 5.4 | 14 |
| 167 | Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. European Journal of Medicinal Chemistry, 2011, 46, 1622-1629. | 5.5 | 14 |
| 168 | S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/Î±<sub>2</sub>-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 750-764. | 2.5 | 14 |
| 169 | A zinc chelator inhibiting gelatinases exerts potent in vitro anti-invasive effects. European Journal of Pharmacology, 1998, 351, 225-233. | 3.5 | 13 |
| 170 | Design, Synthesis and In Vitro Evaluation of Novel Derivatives as Serotonin N -Acetyltransferase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 409-414. | 5.2 | 13 |
| 171 | High-throughput screening assay for new ligands at human melatonin receptors. Acta Pharmacologica Sinica, 2008, 29, 1515-1521. | 6.1 | 13 |
| 172 | Effect of Oxime Ether Incorporation in Acyl Indole Derivatives on PPAR Subtype Selectivity. ChemMedChem, 2012, 7, 2179-2193. | 3.2 | 13 |
| 173 | Molecular basis of agonist docking in a human <scp>GPR</scp>103 homology model by siteâ€directed mutagenesis and structureâ€“activity relationship studies. British Journal of Pharmacology, 2014, 171, 4425-4439. | 5.4 | 13 |
| 174 | New MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists. International Journal of Molecular Sciences, 2017, 18, 1347. | 4.1 | 13 |
| 175 | Apigenin and Luteolin Regulate Autophagy by Targeting NRH-Quinone Oxidoreductase 2 in Liver Cells. Antioxidants, 2021, 10, 776. | 5.1 | 13 |
| 176 | N-Myristoyl-transferase activity in cancer cells. Solubilization, specificity and enzymatic inhibition of a N-Myristoyl transferase from L1210 microsomes. FEBS Journal, 1991, 201, 257-263. | 0.2 | 12 |
| 177 | Chromatographic Assay and Peptide Substrate Characterization of Partially Purified Farnesyl- and Geranylgeranyltransferases from Rat Brain Cytosol. Archives of Biochemistry and Biophysics, 1998, 354, 83-94. | 3.0 | 12 |
| 178 | Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models. Frontiers in Endocrinology, 2012, 3, 160. | 3.5 | 12 |
| 179 | Characterization of cofactors, substrates and inhibitor binding to flavoenzyme quinone reductase 2 by automated supramolecular nano-electrospray ionization mass spectrometry. International Journal of Mass Spectrometry, 2012, 312, 87-96. | 1.5 | 12 |
| 180 | High-Throughput Screening for GPR119 Modulators Identifies a Novel Compound with Anti-Diabetic Efficacy in db/db Mice. PLoS ONE, 2013, 8, e63861. | 2.5 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | UDP-glucuronosyltransferase activities in human liver microsomes and in some laboratory animal species. Biochemical Pharmacology, 1981, 30, 2507-2510. | 4.4 | 11 |
| 182 | Effect of pretreatment with hydroxylated xenobiotics on the activities of rat liver UDP-glucuronosyl-transferases. Xenobiotica, 1983, 13, 755-761. | 1.1 | 11 |
| 183 | Further validation of the Mulder and van Doorn kinetic procedure for the measurement of microsomal UDP-glucuronosyltransferase activities. Biochemical Journal, 1988, 252, 930-931. | 3.7 | 11 |
| 184 | Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60. FEBS Journal, 1993, 214, 503-514. | 0.2 | 11 |
| 185 | Physico-chemical and biological analysis of true combinatorial libraries. Biomedical Applications, 1999, 725, 17-37. | 1.7 | 11 |
| 186 | SVK14 cells express an MCH binding site different from the MCH1 or MCH2 receptor. Biochemical and Biophysical Research Communications, 2002, 295, 841-848. | 2.1 | 11 |
| 187 | The use ofÂIRES-based bicistronic vectors allows theÂstable expression ofÂrecombinant G-protein coupled receptors such asÂNPY5 andÂhistamine 4. Biochimie, 2006, 88, 737-746. | 2.6 | 11 |
| 188 | Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-Dimethyl-3,4-dihydro-1H-quinolin-2-one. European Journal of Medicinal Chemistry, 2008, 43, 1730-1736. | 5.5 | 11 |
| 189 | Molecular mechanisms of transcriptional control by Revâ€erbÎ±: An energetic foundation for reconciling structure and binding with biological function. Protein Science, 2015, 24, 1129-1146. | 7.6 | 11 |
| 190 | W2476 ameliorates Î²-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway. Acta Pharmacologica Sinica, 2017, 38, 1024-1037. | 6.1 | 11 |
| 191 | Inhibition of microsomal NAD(P)H oxidation by Triton X-100. Journal of Proteomics, 1986, 13, 171-178. | 2.4 | 10 |
| 192 | Liquid chromatographic assay for the measurement of glucuronidation of arylcarboxylic acids using uridine diphospho-[U-14C]glucuronic acid. Biomedical Applications, 1986, 383, 51-60. | 1.7 | 10 |
| 193 | Partial purification and characterization of a new p36/40 tyrosine protein kinase from HL-60. Biochemical and Biophysical Research Communications, 1989, 160, 1203-1211. | 2.1 | 10 |
| 194 | Synthesis of new arylalkoxy amido derivatives as melatoninergic ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 789-800. | 3.0 | 10 |
| 195 | Design, Synthesis and In Vitro Evaluation of Novel Benzo[b]thiophene Derivatives as Serotonin N-acetyltransferase (AANAT) Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 119-125. | 5.2 | 10 |
| 196 | S38151 [p-guanidinobenzoyl-[Des-Gly10]-MCH(7-17)] is a potent and selective antagonist at the MCH1 receptor and has anti-feeding properties in vivo. Peptides, 2009, 30, 1997-2007. | 2.4 | 10 |
| 197 | Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. Life Sciences, 2011, 89, 259-268. | 4.3 | 10 |
| 198 | Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG. International Journal of Molecular Sciences, 2019, 20, 3181. | 4.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Journal of pineal research guideline for authors: Defining and characterizing melatonin targets. Journal of Pineal Research, 2021, 70, e12712. | 7.4 | 10 |
| 200 | Heterogeneity of hepatic UDP-Glucuronosyltransferase activities: Investigations of isoenzymes involved in p-nitrophenol glucuronidation. Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 1993, 106, 241-248. | 0.5 | 9 |
| 201 | Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. Canadian Journal of Physiology and Pharmacology, 1997, 75, 683-689. | 1.4 | 9 |
| 202 | High-Capacity Screening of Arylalkylamine N-Acetyltransferase Inhibitors using a High-Performance Liquid Chromatography System. Journal of Biomolecular Screening, 2000, 5, 361-368. | 2.6 | 9 |
| 203 | In vivo characterisation of the human UCP3 gene minimal promoter in mice tibialis anterior muscles. Biochemical and Biophysical Research Communications, 2003, 311, 583-591. | 2.1 | 9 |
| 204 | Assessment of a high-throughput screening methodology for the measurement of purified UCP1 uncoupling activity. Analytical Biochemistry, 2006, 351, 201-206. | 2.4 | 9 |
| 205 | Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II). European Journal of Medicinal Chemistry, 2015, 90, 822-833. | 5.5 | 9 |
| 206 | Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6). Protein Science, 2016, 25, 2225-2242. | 7.6 | 9 |
| 207 | New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation. European Journal of Medicinal Chemistry, 2017, 127, 621-631. | 5.5 | 9 |
| 208 | VHH characterization.Recombinant VHHs: Production, characterization and affinity. Analytical Biochemistry, 2020, 589, 113491. | 2.4 | 9 |
| 209 | Constituents of Chamaecrista diphylla (L.) Greene Leaves with Potent Antioxidant Capacity: A Feature-Based Molecular Network Dereplication Approach. Pharmaceutics, 2021, 13, 681. | 4.5 | 9 |
| 210 | Rat liver microsomal 3Î±-hydroxysteroid dehydrogenase and dihydrodiol dehydrogenase: Solubilization, separation and partial purification. Biochemical and Biophysical Research Communications, 1986, 135, 795-801. | 2.1 | 8 |
| 211 | Tyrosine protein kinase assays. Biomedical Applications, 1996, 684, 179-199. | 1.7 | 8 |
| 212 | Synthesis of 5-Substituted-2,3-dihydro-1,4-benzoxathiins: Biological Evaluation as Melatonin Receptors Ligands. Journal of Enzyme Inhibition and Medicinal Chemistry, 2003, 18, 187-193. | 5.2 | 8 |
| 213 | Design and Synthesis of Indole and Tetrahydroisoquinoline Hydantoin Derivatives as Human Chymase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2004, 19, 137-143. | 5.2 | 8 |
| 214 | Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HLâ€60. International Journal of Peptide and Protein Research, 1994, 43, 496-504. | 0.1 | 8 |
| 215 | 19F nuclear magnetic resonance screening of glucokinase activators. Analytical Biochemistry, 2015, 477, 62-68. | 2.4 | 8 |
| 216 | Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives. European Journal of Medicinal Chemistry, 2016, 109, 360-370. | 5.5 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Hamster Melatonin Receptors: Cloning and Binding Characterization of MT1 and Attempt to Clone MT2. International Journal of Molecular Sciences, 2018, 19, 1957. | 4.1 | 8 |
| 218 | Natural Inhibitors of the RhoAâ€“p115 Complex from the Bark of Meiogyne baillonii. Journal of Natural Products, 2018, 81, 1610-1618. | 3.0 | 8 |
| 219 | Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates. Molecules, 2019, 24, 3697. | 3.8 | 8 |
| 220 | Chemical composition and antibacterial action of Stryphnodendron pulcherrimum bark extract, â€œbarbatimÃ£oâ€•species: Evaluation of its use as a topical agent. Arabian Journal of Chemistry, 2021, 14, 103183. | 4.9 | 8 |
| 221 | Use of the main tyrosine protein kinase activity purified from HL-60 in the search for a new class of anticancer compounds. Anticancer Research, 1990, 10, 197-201. | 1.1 | 8 |
| 222 | Approaches to some biochemical mechanisms of action of tuftsin and analogues. Biochemical Pharmacology, 1991, 41, 1411-1418. | 4.4 | 7 |
| 223 | Relationship between the cellular accumulation and the cytotoxicity of S12363, a new vinca alkaloid derivative. Cancer Chemotherapy and Pharmacology, 1992, 29, 367-374. | 2.3 | 7 |
| 224 | Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT 2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 549-554. | 3.0 | 7 |
| 225 | Development of new assays and improved procedures for the purification of recombinant human chymase. FEBS Journal, 2001, 268, 5885-5893. | 0.2 | 7 |
| 226 | A microplate assay for the screening of ADAMTS-4 inhibitors. Matrix Biology, 2006, 25, 261-267. | 3.6 | 7 |
| 227 | Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives. Molecules, 2017, 22, 210. | 3.8 | 7 |
| 228 | Identification of catalytic and nonâ€catalytic activity inhibitors against PRC2â€EZH2 complex through multiple highâ€throughput screening campaigns. Chemical Biology and Drug Design, 2020, 96, 1024-1051. | 3.2 | 7 |
| 229 | In vitro evaluation of glucuronidation of monohydroxylated aglycones related to quantum chemically-calculated parameters. European Journal of Medicinal Chemistry, 1987, 22, 393-402. | 5.5 | 6 |
| 230 | A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot. Journal of Biological Chemistry, 2018, 293, 9064-9077. | 3.4 | 6 |
| 231 | How Can Molecular Pharmacology Help Understand the Multiple Actions of Melatonin: 20 Years of Research and Trends. , 0, , . | | 6 |
| 232 | General lack of structural characterization of chemically synthesized long peptides. Protein Science, 2019, 28, 857-867. | 7.6 | 6 |
| 233 | MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice. Molecules, 2021, 26, 1291. | 3.8 | 6 |
| 234 | Screening of Ligand Binding on Melatonin Receptor Using Non-Peptide Combinatorial Libraries. Journal of Receptor and Signal Transduction Research, 2000, 20, 105-118. | 2.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay. Cellular Signalling, 2005, 17, 489-496. | 3.6 | 5 |
| 236 | Mutagenic analysis in a pure molecular system shows that thioredoxinâ€interacting protein residue Cys247 is necessary and sufficient for a mixed disulfide formation with thioredoxin. Protein Science, 2012, 21, 1323-1333. | 7.6 | 5 |
| 237 | Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative. Journal of Medicinal Chemistry, 2018, 61, 10185-10197. | 6.4 | 5 |
| 238 | Image-free assessment of protein translocation in live cells. Current Opinion in Pharmacology, 2009, 9, 650-656. | 3.5 | 4 |
| 239 | Synthesis, chiral resolution, absolute configuration assignment and pharmacological evaluation of a series of melatoninergic ligands. MedChemComm, 2014, 5, 1303-1308. | 3.4 | 4 |
| 240 | Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides. Analytical Biochemistry, 2017, 519, 57-70. | 2.4 | 4 |
| 241 | Secure and Sustainable Sourcing of Plant Tissues for the Exhaustive Exploration of Their Chemodiversity. Molecules, 2020, 25, 5992. | 3.8 | 4 |
| 242 | Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries. Canadian Journal of Physiology and Pharmacology, 1997, 75, 683-9. | 1.4 | 4 |
| 243 | UDP-glucuronosyltransferase(S) activities towards natural substrates in rat liver microsomes. Kinetic properties and influence of Triton X-100 activation. Pharmacological Research Communications, 1985, 17, 1005-1015. | 0.2 | 3 |
| 244 | Heterogeneity of Hepatic Microsomal UDP-Glucuronosyltransferase(s) Activities: A New Kinetic Approach for the Study of Induction and Specificity. Journal of Pharmaceutical Sciences, 1994, 83, 591-596. | 3.3 | 3 |
| 245 | From peptide libraries to optimized nonpeptide ligands in the search for S-farnesyltransferase inhibitors. Chemical Biology and Drug Design, 2001, 57, 85-96. | 1.1 | 3 |
| 246 | Receptor- and Ligand-Based Study on Novel 2,2â€²-Bithienyl Derivatives as Non-Peptidic AANAT Inhibitors. Journal of Chemical Information and Modeling, 2010, 50, 446-460. | 5.4 | 3 |
| 247 | A Quantitative Assay for Lysosomal Acidification Rates in Human Osteoclasts. Assay and Drug Development Technologies, 2011, 9, 157-164. | 1.2 | 3 |
| 248 | Fluorescent analogues of BeKm-1 with high and specific activity against the hERG channel. Toxicon: X, 2019, 2, 100010. | 2.9 | 3 |
| 249 | Synthesis of a Novel Series of 8-HETE Analogs and their Biological Evaluation Towards the PPAR Nuclear Receptors. Letters in Drug Design and Discovery, 2008, 5, 503-511. | 0.7 | 3 |
| 250 | Further assessments of ligase LplA-mediated modifications of proteins in vitro and in cellulo. Molecular Biology Reports, 2022, 49, 149-161. | 2.3 | 3 |
| 251 | Parallel synthesis and pharmacological screening of nonpeptide ligands of the neuropeptide Y receptor subtype Y5. Chemical Biology and Drug Design, 2001, 57, 419-427. | 1.1 | 2 |
| 252 | Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 653-672. | 5.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | On the Organization of a Drug Discovery Platform. , 2018, , . | | 2 |
| 254 | Association of NQO2 With UDP-Glucuronosyltransferases Reduces Menadione Toxicity in Neuroblastoma Cells. Frontiers in Pharmacology, 2021, 12, 660641. | 3.5 | 2 |
| 255 | Biochemistry, structure, and cellular internalization of a four nanobodyâ€bearing Fc dimer. Protein Science, 2021, 30, 1946-1957. | 7.6 | 2 |
| 256 | Melanin-concentrating hormone receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, . | 0.2 | 2 |
| 257 | A Putative New Melatonin Binding Site in Sheep Brain, MTx: Preliminary Observations and Characteristics. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 76-89. | 2.5 | 2 |
| 258 | Caloxin-derived peptides for the inhibition of plasma membrane calcium ATPases. Peptides, 2022, 154, 170813. | 2.4 | 2 |
| 259 | Heterogeneity of hepatic microsomal UDP-glucuronosyltransferases activities: use and comparison of differential inductions in some mamalian species. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1987, 87, 513-522. | 0.2 | 1 |
| 260 | Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study. Molecules, 2021, 26, 4312. | 3.8 | 1 |
| 261 | Jean - Luc Fauchereâ€,(1941-2003). Chemical Biology and Drug Design, 2003, 62, 185-185. | 1.1 | 0 |
| 262 | Progress and new fields in molecular pharmacology. Current Opinion in Pharmacology, 2009, 9, 577-579. | 3.5 | 0 |